ACC latest: Lilly, Merck, Pfizer, Novartis and more unveil key data

Tracy Staton You missed the American College of Cardiology meeting. That's OK. The most newsworthy research coming out of the meeting is gathered right here, with almost every Big ...

VC-backed public offerings at lowest ebb since 2011

Ben Adams Six venture-backed IPOs raised just $ 574.5 million in the first quarter of 2016, according to the Exit Poll Report, marking the slowest quarter for these types of offerings ...

Follow-on bonanza drives U.K. investment in life science stocks past £1B

Nick Paul Taylor At first glance, 2015 looks like the year the London Stock Exchange turned its back on biotech once again. Acacia Pharma and Shield Therapeutics both tried and failed ...

Merck treads water in Q4 as Keytruda helps offset Remicade suffering

Tracy Staton Merck & Co. took a one-two punch in the fourth quarter. Revenue from two top-selling franchises–Januvia and Remicade–slid, dragging overall ...

Facing extinction, MannKind is reportedly looking to sell itself

Damian Garde Struggling drugmaker MannKind is looking for a way out of its perilous financial situation, according to Reuters, scouting for a buyer in the wake of ex-partner Sanofi's ...

Gilead faces legal action in Massachusetts if it doesn’t cut hep C prices: State AG

Tracy Staton Gilead Sciences is facing more hepatitis C pushback from state officials. The Massachusetts attorney general is warning that it will take legal action against the California-based ...

Big Pharma chalks up victory in Arizona Supreme Court over Rx safety warnings

Emily Wasserman Big Pharma can celebrate a bright point. Arizona's top court ruled that drugmakers don't have an obligation to warn patients directly about safety risks of their ...

Galapagos’ bowel drug misses the mark in Phase II

Damian Garde Belgian biotech Galapagos is shutting down an ulcerative colitis program after its top prospect failed to make a difference in a Phase II trial, putting off plans for late-stage ...

Indian pharma mulls deal for U.S. injectables maker Sagent Pharma

Emily Wasserman U.S. injectables maker Sagent Pharmaceuticals is considering putting itself on the chopping block, and if or when it does, at least 5 Indian drugmakers could come calling. FiercePharma ...

Glaxo CEO: Consumer health can stand on its own, but don’t expect a quick spinoff

Carly Helfand Lately, GlaxoSmithKline CEO Andrew Witty has seemed open to splitting off the industry-leading consumer health joint venture he formed with Novartis last year. But let ...

UPDATED: Alkermes slammed as top depression drug fails two PhIIIs

John Carroll Alkermes reported this morning that its closely watched depression drug ALKS-5461 failed to hit the primary endpoints in the first two of three Phase III studies, slamming ...

Pfizer looks to Russian partnership to produce some of its meds there, report says

Eric Palmer Russia's economy has gotten ugly in the past few years, but that has not dampened the enthusiasm of Big Pharma, which continues to like the look of one of the world's ...
Page 1 of 4112345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS